![Brian Hubbard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Brian Hubbard worked at Dogma Therapeutics, Inc. from 2015 to 2021 as President, CEO, Secretary, Treasurer & Director.
From 2018 to 2024, Dr. Hubbard was Chief Executive Officer at Anji Pharmaceuticals, Inc. Dr. Hubbard also worked at Metsera, Inc. as Chief Scientific Officer from 2023 to 2025.
Dr. Hubbard completed undergraduate studies at The College of William & Mary and earned a doctorate from the University of Illinois.
Eerdere bekende functies van Brian Hubbard
| Bedrijven | Functie | Einde |
|---|---|---|
Anji Pharmaceuticals, Inc.
 Anji Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery and development of medicines for human genetics | Algemeen Directeur | 01-04-2024 |
Dogma Therapeutics, Inc.
 Dogma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease | Algemeen Directeur | 01-11-2021 |
Opleiding van Brian Hubbard
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
17
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
The College of William & Mary
 The College of William & Mary Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
 University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anji Pharmaceuticals, Inc.
Anji Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery and development of medicines for human genetics | Health Technology |
Dogma Therapeutics, Inc.
Dogma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease | Health Technology |
